#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Colorectal cancer metastatic Obesity Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Dementia Alzheimer's type Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Angiosarcoma non-metastatic Cardiac amyloidosis Non-Hodgkin's lymphoma unspecified histology aggressive recurrent Malignant fibrous histiocytoma Selective polysaccharide antibody deficiency Microvillous inclusion disease Cholestatic pruritus Thyroid cancer metastatic Peritoneal mesothelioma malignant Palmar-plantar erythrodysaesthesia syndrome Transitional cell cancer of the renal pelvis and ureter Langerhans' cell histiocytosis Cataract Primary mediastinal large B-cell lymphoma Ductal adenocarcinoma of pancreas More trials…

    Learn about Rare Diseases

    Optic glioma – Trials in Disease Rhabdoid tumour KBG syndrome – Diagnostics Lymphangioma – Trials in Disease VEXAS syndrome – Basic Information Leiomyosarcoma recurrent Hereditary angioedema – Treatment Ocular melanoma – Life with Disease Lysosomal storage disorder – Basic Information Pemphigus – Life with Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Cefoxitin Sildenafil Azd8421 Iodixanol Tinzaparin Bosutinib Betamethasone Acetate GRAPHITE Clindamycin Digitoxin Azd5004 Bhv-7000 Paclitaxel Albumin-Bound ALPROSTADIL Metyrapone Bp 1,3-BUTYLENE GLYCOL Dexamethasone Sodium Phosphate Pravastatin Sodium Guselkumab Cannabis Sativa Flower More therapies…

    Learn about Your Condition

    T-cell type acute leukaemia Polymyalgia rheumatica Death neonatal Polycystic ovarian syndrome Becker's muscular dystrophy Mitochondrial myopathy Cluster headache Lichenoid keratosis Factor VIII deficiency Relapsing multiple sclerosis HER2 protein overexpression Endometrial cancer stage II Bronchiectasis Pulmonary resection Dyslipidaemia More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Hemic and Lymphatic Diseases

  • Study Comparing Belantamab Mafodotin with Lenalidomide and Dexamethasone to Daratumumab with Lenalidomide and Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Belantamab Mafodotin
    • Dexamethasone Ph. Eur.
    • Daratumumab
    Austria Belgium Czechia France Germany Greece +5

  • Study on the Safety of Eganelisib Alone and with Cytarabine for Patients with Relapsed or Refractory Acute Myeloid Leukemia or Higher-Risk Myelodysplastic Syndromes

    Recruiting

    1 1 1 1
    Investigated Diseases:
    • Acute myeloid leukaemia recurrent
    • Acute myeloid leukaemia refractory
    Investigated Drugs:
    • EGANELISIB
    • Cytarabine
    Spain

  • Long-term Follow-up Study for Patients with Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia/Lymphoma Treated with OC-1 Cells

    Recruiting

    3 1 1
    Investigated Drugs:
    • Autologous T-Cells Ex Vivo Modified With A Lentiviral Vector Encoding A Chimeric Antigen Receptor Specific For Cd1A
    Spain

  • Study of Elritercept for Treating Anemia in Adults with Low to Intermediate Risk Myelodysplastic Syndromes

    Recruiting

    3 1
    Investigated Drugs:
    • Elritercept
    Bulgaria Czechia France Germany Hungary Ireland +5

  • Study on Oral Arsenic Trioxide for Patients with Low-Risk Myelodysplastic Syndromes Not Responding to Erythropoiesis Stimulating Agents and Luspatercept

    Recruiting

    1 1 1
    Investigated Drugs:
    • Arsenic Trioxide
    France

  • Study on the Safety and Effectiveness of Etranacogene Dezaparvovec Gene Therapy for Adults with Severe or Moderately Severe Hemophilia B and AAV5 Antibodies

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Factor IX deficiency
    Investigated Drugs:
    • Etranacogene Dezaparvovec
    Bulgaria Poland
Previous Page
1 … 9 10 11 12 13 … 89
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!